NEW YORK (GenomeWeb News) – Danaher today said that it has completed its $19.50-per-share offer to acquire Iris International.

The $338 million deal was signed by the firms in September. The purchase price represented a 45 percent premium to Iris' closing stock price of $13.42 on Sept. 14, the day before the agreement was announced.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.